Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00675298
Other study ID # 2010P000226
Secondary ID R01DK081647
Status Completed
Phase N/A
First received May 7, 2008
Last updated February 2, 2017
Start date January 2006
Est. completion date June 2011

Study information

Verified date February 2014
Source Beth Israel Deaconess Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Urologic pelvic pain syndrome (UCPPS), variably termed painful bladder syndrome/interstitial cystitis (PBS/IC) in females and chronic prostatitis/chronic pelvic pain syndrome in men (CP/CPPS), is a chronic, debilitating clinical syndrome presenting as severe pelvic pain with extreme urinary urgency and frequency in the absence of any known cause. The etiologic mechanisms underlying UCPPS are unknown, but recurrence, risks to siblings of affected individuals, concordance among monozygotic twins, and our own preliminary studies indicate a strong genetic contribution to the cause of UCPPS. The overall goal of this proposal is use novel approaches to understand the basis of UCPPS, to identify candidate genes containing mutations that result in UCPPS and determine how the different encoded proteins of these genes interact with one another in a common biological pathway. Ultimately, understanding how mutations in at least five different genes yield the symptoms of UCPPS should lead to improved diagnosis and possible therapies.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date June 2011
Est. primary completion date June 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Years to 80 Years
Eligibility Inclusion Criteria:

- Have symptoms for at least 3 months within the preceding 6 months:

- Pain in the pelvic area

- Urinary frequency and/or

- Urinary urgency and/or

- Sexual dysfunction (erectile dysfunction)

- Have CP/CPPS, IC, PBS, or BFS

- Be willing to provide a saliva and urine sample

- Agree to complete several brief questionnaires

- Family of someone with CP/CPPS, PBS, IC or BFS

- Live in the USA or Canada

Exclusion Criteria:

- Major structural/anatomical urinary tract abnormalities

- Underlying inborn or congenital conditions

Study Design


Locations

Country Name City State
United States Jordan D Dimitrakoff Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Beth Israel Deaconess Medical Center National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Dimitrakov J, Joffe HV, Soldin SJ, Bolus R, Buffington CA, Nickel JC. Adrenocortical hormone abnormalities in men with chronic prostatitis/chronic pelvic pain syndrome. Urology. 2008 Feb;71(2):261-6. doi: 10.1016/j.urology.2007.09.025. — View Citation

Dimitrakov J, Kroenke K, Steers WD, Berde C, Zurakowski D, Freeman MR, Jackson JL. Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review. Arch Intern Med. 2007 Oct 8;167(18):1922-9. Review. Erratum in: Arch Intern Med. 2007 Dec 10-22;167(22):2452. — View Citation

Dimitrakov JD, Kaplan SA, Kroenke K, Jackson JL, Freeman MR. Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach. Urology. 2006 May;67(5):881-8. Review. — View Citation

Dimitrakov JD. A case of familial clustering of interstitial cystitis and chronic pelvic pain syndrome. Urology. 2001 Aug;58(2):281. — View Citation

See also
  Status Clinical Trial Phase
Recruiting NCT06201013 - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children N/A
Recruiting NCT05880862 - Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls Early Phase 1
Recruiting NCT04807920 - BOTOX® at the Time of Prolapse Surgery for OAB Phase 4
Terminated NCT02385500 - Fesoterodine on Urgency Episodes in Parkinson's Disease Population Phase 4
Not yet recruiting NCT02477241 - Brain Areas Involved in Bladder Filling and Contraction N/A
Completed NCT01698138 - Prevention of Bladder Dysfunction in Acute Spinal Cord Injury Phase 4
Completed NCT00527033 - A Study of YM178 in Patients With Symptomatic Overactive Bladder Phase 2
Completed NCT00613327 - An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants Phase 4
Completed NCT00368706 - A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients Phase 3
Recruiting NCT04305743 - Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A Phase 4
Active, not recruiting NCT03681678 - Laser Therapy for Treatment of Urogenital Symptoms in Women
Completed NCT01655069 - A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 Phase 3
Completed NCT01558856 - Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder N/A
Completed NCT01521767 - Pharmacokinetics and Relative Bioavailability Study Phase 1
Completed NCT01194999 - Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence Phase 4
Completed NCT01157377 - Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence Phase 2
Completed NCT01381120 - Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms Phase 4
Completed NCT01262391 - Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents Phase 1
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Completed NCT02849418 - Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity Phase 3